NEW YORK (GenomeWeb News) – Canadian biotechnology firm Norgen Biotek today announced a C$800,000 (US$821,000) award from the National Research Council of Canada Industrial Research Assistance Program, which the company will use to develop point-of-care diagnostic technologies.
The technologies, Norgen said, will be directed for use in settings with limited resources. The company will focus its development efforts on non-invasive, urine-based, rapid detection systems for diagnosing sexually transmitted infections and other diseases, such as tuberculosis.
Norgen added that it will be partnering with an unnamed Spanish diagnostic firm in the R&D work.
Based in Thorold, Ontario, Norgen is focused on developing sample preparation kits for DNA, RNA, and protein purification, and diagnostic tools.
"Such funding will help us in the transition of our powerful nucleic acid isolation technology into diagnostics applications," Yousef Haj-Ahmad, president and CEO of Norgen, said in a statement.